<SEC-DOCUMENT>0001437749-22-012031.txt : 20220512
<SEC-HEADER>0001437749-22-012031.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512101401
ACCESSION NUMBER:		0001437749-22-012031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PETMED EXPRESS INC
		CENTRAL INDEX KEY:			0001040130
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				650680967
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28827
		FILM NUMBER:		22916225

	BUSINESS ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
		BUSINESS PHONE:		(561) 426-4444

	MAIL ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pets20220511_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:pets="http://www.pets.com/20220509"><head>
	<title>pets20220511_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 5/12/2022 11:57:00 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001040130</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="pets-20220509.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-05-09</xbrli:startDate>
<xbrli:endDate>2022-05-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b><br />
<b>SECURITIES AND EXCHANGE COMMISSION</b><br />
<b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b><br />
<b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 9, 2022</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="1" style="vertical-align:top;width:96.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b><span style="text-decoration: underline;">PetMed Express, Inc.</span></b></ix:nonNumeric><br />
			&#xa0;(Exact name of registrant as specified in its charter)</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b><span style="text-decoration: underline;">Florida</span></b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b><span style="text-decoration: underline;">000-28827</span></b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b><span style="text-decoration: underline;">65-0680967</span></b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(State or other jurisdiction<br />
			of incorporation)</div>
			</td>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(Commission<br />
			File Number)</div>
			</td>
			<td style="vertical-align:top;width:20%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(I.R.S. Employer<br />
			Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:100%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b><span style="text-decoration: underline;">420 South Congress Avenue</span></b></ix:nonNumeric><b><span style="text-decoration: underline;">, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b><span style="text-decoration: underline;">Delray Beach</span></b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressStateOrProvince"><b><span style="text-decoration: underline;">FL</span></b></ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b><span style="text-decoration: underline;">33445</span></b></ix:nonNumeric></span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:100%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(Address of principal executive offices) (Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:97.8%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><b><span style="text-decoration: underline;">(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b><span style="text-decoration: underline;">561</span></b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b><span style="text-decoration: underline;">526-4444</span></b></ix:nonNumeric></span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:97.8%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(Registrant&#8217;s telephone number, including area code)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:100%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;"><b><span style="text-decoration: underline;">Not Applicable</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:100%;">
			<div style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; text-align: center; margin: 0pt;">(Former name or former address, if changed since last report)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:3.5%;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></td>
			<td style="vertical-align:top;width:96.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:96.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></td>
			<td style="vertical-align:top;width:96.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:96.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></td>
			<td style="vertical-align:top;width:96.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:96.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.5%;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></td>
			<td style="vertical-align:top;width:96.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Trading Symbol(s)</div>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Name of each exchange on which</div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">registered</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock, par value $.001 per share</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">PETS</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Select Market</ix:nonNumeric></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company <ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On May 9, 2022, PetMed Express, Inc. (the &#8220;Company&#8221;) held a conference call to discuss its financial results for the quarter and year ended on March 31, 2022. A copy of this conference call transcript is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information in this Item 2.02 and the information contained in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01</b>&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:10.1%;">&#xa0;</td>
			<td style="vertical-align:top;width:3.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</div>
			</td>
			<td style="vertical-align:top;width:86.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibits.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10.1%;">&#xa0;</td>
			<td style="vertical-align:top;width:3.2%;">&#xa0;</td>
			<td style="vertical-align:top;width:86.7%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10.1%;">&#xa0;</td>
			<td style="vertical-align:top;width:3.2%;">&#xa0;</td>
			<td style="vertical-align:top;width:86.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1 &#8211;&#xa0;PetMed Express, Inc. conference call transcript dated May 9, 2022.</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104 &#8211;&#xa0;Cover Page Interactive Data File (formatted as Inline XBRL).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT INDEX</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:10.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Exhibit No.</span></div>
			</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
			<td style="vertical-align:top;width:85%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Description</span></div>
			</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
			<td style="vertical-align:top;width:85%;">&#xa0;</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
			<td style="vertical-align:top;width:85%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_374831.htm" style="-sec-extract:exhibit;">PetMed Express, Inc. conference call transcript dated May 9, 2022.</a></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</div>
			</td>
			<td style="vertical-align:top;width:2.2%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: May 12, 2022</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:49.9%;">&#xa0;</td>
			<td colspan="2" style="vertical-align:top;width:50.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PETMED EXPRESS, INC.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:6%;">&#xa0;</td>
			<td style="vertical-align:top;width:44%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="vertical-align:top;width:44%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">/s/ Bruce S. Rosenbloom</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</div>
			</td>
			<td style="vertical-align:top;width:44%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bruce S. Rosenbloom</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</div>
			</td>
			<td style="vertical-align:top;width:44%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_374831.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_374831.htm</title>

	<!-- Generated by ThunderDome Portal - 5/12/2022 5:46:00 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Exhibit 99.1 Page " data-startnum="1" data-suffix=" of 11" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Exhibit 99.1</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PETMED EXPRESS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>QUARTER AND YEAD ENDED MARCH 31, 2022</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONFERENCE CALL TRANSCRIPT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MAY 9, 2022 AT 4:30 P.M. ET</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Welcome to PetMeds&#8217; conference call to review the financial results for the fourth quarter and fiscal year end March 31, 2022. During the presentation all participants will be in a listen only mode. Afterwards we will conduct a question-and- answer session, at that time if you have a question, please press the one followed by the four on your telephone. If at any time during the conference you need to reach an operator, please press star zero. At the request of the Company, this conference call is being recorded. Founded in 1996, PetMeds is your trusted pet health expert and America&#8217;s most trusted pet pharmacy delivering prescription and non-prescription pet medications and other health products for dogs, cats and horses direct to the customer. PetMeds&#8217; markets its products through national advertising campaigns, which direct customers to order online or by phone and which are intended to increase the recognition of the PetMeds brand name. PetMeds provides an attractive alternative for obtaining pet medications in terms of convenience, price, ease of ordering and rapid home delivery. At this time, I would like to turn the call over to the Company&#8217;s Chief Financial Officer, Mr. Bruce Rosenbloom.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thank you. And I&#8217;d like to welcome everybody here today. I would also like to remind everyone that the first portion of this conference call will be listen-only until the question-and-answer session, which will be later in the call. Also, certain information that will be included in this press conference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or the Securities and Exchange Commission that may involve a number of risks and uncertainties. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results could differ materially from those projected. The Company undertakes no obligation to update these statements based on subsequent events. We have identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission. Now let me introduce our CEO and President, Matt Hulett.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thanks, Bruce. Good afternoon and thank you for joining us. This earnings call is the eight-month mark since I started as the new CEO and President of PetMeds. Throughout this time, I remain committed to clarity and transparency with investors and key stakeholders as to the progress of our strategic transformation. To be clear, PetMeds pioneered the online pet prescription business over 26 years ago and that is a legacy of which everyone at PetMeds is very proud. However, in recent years, growth has slowed, and outside of a significant 2020 uptick in sales related to the pandemic, our leadership position has slipped. I continue to believe the PetMeds is a terrific company with a talented and dedicated workforce serving a large and loyal customer base. During today&#8217;s earnings call, we will share with you some early indications regarding the stabilization of our core business an articulation of our new strategy and tangible evidence of operating progress towards the execution of that new strategy. I reiterate that my commitment is to be open and transparent as to how we are engineering the transformation of this iconic company. Today, I&#8217;m going to divide my prepared remarks between our core prescription business and our pet health expert strategy, with more time spent on the latter, including some specific steps we have already taken towards executing on this broader strategy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I have a number of key points I want to communicate to you today. So for clarity. I&#8217;ve organized them into three themes. The first theme is the stabilization of the core business where the significant revenue declines, we&#8217;ve experienced over the past year, have begun to moderate. For example, our revenue in the fourth quarter decreased 7.9% year-over-year compared to a decrease of 12.7% for the preceding nine-month period. While January and February had revenue declines in the low single digits, weather in March had a more material impact on our quarter. Specifically, a cooler March in much of the country delayed the start of the flea and tick season, a season which normally represent a ramp-up in customer demand for us, leading to a slower-than-expected final month of the quarter. We expect sales in this category to rebound, as higher temperatures return to much of the country and stimulate a more normal flea and tick and heartworm medication demand from pet parents. Based on historic customer purchase patterns, we expect that the sales impact for&nbsp;this year will be a delay to the start of these seasonal sales rather than a compression or loss of sales over the course of this summer. Adjusted EBITDA for the fourth quarter exceeded our expectations by being down only 8.4%, as compared to the 31% decrease reported for the third quarter. Bruce will cover this in more detail, but we achieved these results despite double-digit percent increases in general and administrative expenses year-over-year due to purposeful investments in headcount and infrastructure to stimulate and support our future growth.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 1 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notably, we kept our variable marketing spend relatively flat year-over-year. As you may recall, last quarter we had a test-and-learn quarter that resulted in unexpected inefficiency in our marketing spend. We have now settled into a good place with our marketing operations. We are actively testing our key customer learnings from last quarter and remain laser-beam focused on activities to grow our new customer number. While we have not fully cracked the code on new customer growth, we are executing on several strategic steps, having just started our new customer segmentation strategy, and recently bringing our new team members, like our new Chief Marketing Officer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The second theme is the acceleration of our subscription business. Today, I&#8217;m pleased to report that as of the month of March, 37% of our revenue is recurring revenue derived from our AutoShip &amp; Save subscription program. This is a whopping 41% increase from the previous quarter. As mentioned in our last earnings call, we are introducing two new metrics that are strategically important as our business evolves into a subscription e-commerce business. As a result of this evolution, over time we expect to see an increase in our LTV (life-time value), as the subscription program creates a more reliable recurring revenue stream from our customers. Our new customer count for the quarter is approximately 66,000 and our LTV to CAC (customer acquisition cost) for the quarter is 2.5X. The new customer count is calculated using the more specific definition of new customers as being those who have not previously purchased from us within the past three years. As I mentioned earlier, we believe LTV to CAC is a more meaningful measure of the marketing value creation versus using our traditional ROAS (return on advertising spend) metric. We expect to see that LTV to CAC number grow as we migrate more of our returning customers to our AutoShip subscription program and expand the basket size or average order value over the life of our customers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The final theme is the rapid acceleration of our pet health expert strategy with the first building block of the strategic pillar being telemedicine. On April 19, we announced our initial deployment of an investment in partnership strategy that greatly accelerates our experts in pet health strategy. You may recall on that date, we announced an exclusive partnership with the fastest growing and industry leading telemedicine platform, Vetster. This is the exciting first of many transactions that will build the strategic pillar of our expert pet health strategy. I hinted at telemedicine during our last call, and to enter this space we delivered a novel approach to capital allocation that I will talk about a bit later on this call.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Now let us dive deeper into the details with the presentation material. As always, we like the future pictures of our customers&#8217; and employees&#8217; pets in our slide decks. You will see in many original pictures throughout this presentation. In fact, this slide features my dog, Harry, a PetMeds customer since he was eight weeks old.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Let us start with a look at the current market and a perspective on the overall opportunity. As we covered in our previous earnings calls, PetMeds operates in a very large and growing addressable market. The U.S. pet market is over $100 billion in annual sales, and it is expected to reach $120 billion by 2024. The addressable pet medication market where we participate today is approximately $10 billion and growing rapidly. We are actively working on improving our core business that has been on the decline, while also setting our sights on expanding our addressable market into the broader wellness market, which is estimated to be over $30 billion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Today, we are one of the leading pet pharmacies. PetMeds is also an important part of the strategy of many of the pet platforms and players in the industry. Additionally, what I&#8217;ve learned over these months since I started the business, there are not many trusted online prescription providers for these pet platforms and players to partner with, which puts us in an enviable position. Our core asset and demonstrated competency around prescriptions will enable us to move much more quickly to execute on our broader pet health expert strategy as I will elaborate on in a moment. Not only are we operating in a large addressable market, but we also operate in a market that is growing with underlying behavioral trends that are favorable to digital retailers. U.S. household pet ownership has increased over time, and today, seven out of ten US households have a pet. COVID has accelerated this trend and now more than ever, pet parents are keenly attuned to the health needs of their pets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In a post-COVID world, those pet parents are going to need and will seek out health and wellness care provided by a trusted brand. I believe PetMeds is uniquely positioned to take advantage of this trend. Consumers also now expect everything to be real-time, fast and digital, a trend which has impacted every industry. As we&#8217;ve seen in other digital e-commerce verticals, the ongoing move towards digitization of retail is accelerating.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 2 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Today, our addressable market is largely dominated by offline sales, but we see the growing trend to purchase online as very favorable to us. Pet parents see their pets as an extension of their own families, and they are increasingly demanding more healthy pet care options. We see this is a positive trend for PetMeds and an opportunity for growth. Similarly, aligned with the trends in human health, pet parents are thinking through the entire spectrum of their pet&#8217;s care, from diet to veterinary services, and from infancy through old age, as well as re-examining the channels through which they access those products and services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Lastly, the pandemic accelerated the increasing trend for the digitization of healthcare. Specifically in the pet market, regulations related to in-person veterinary visits and prescription fulfilment were temporarily waived for the first time during COVID and these services moved online in unprecedented ways. As I mentioned in our previous earnings call, our team has spent a considerable amount of time conducting research with the industry generally, as well as specifically with pet parents. As I noted earlier, in April, we announced an important strategic partnership and investment in pet telemedicine with Vetster. With this groundbreaking partnership, we believe we are enabling the first mainstream pet telemedicine platform, and the one that will prove to be an accelerator of widespread adoption of pet telemedicine. It&#8217;s been over a decade where PetMeds has many first and fast mover and my commitment is that we will continue to do so.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the last earnings call, we discussed some key PetMeds differentiators. I want to reiterate those, because they are important, and I believe they provide a real edge for our company&#8217;s transformation. First, our brand is both widely known and trusted. Our own market research indicates that 55% of U.S. pet parents are aware of the PetMeds brand. Having a strong brand takes years to develop and our customers look to PetMeds as their trusted pharmacy and pet medication experts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Second, we have a strong operational and quality efficiency as a pharmacy. Our customer care integration with our pharmacy is world-class, which ensures that customers get their products delivered quickly and accurately. Additionally, our vet partners receive quality service delivered through our vet platform. We will be looking to expand our vet network and provide enhanced service to them with new technology delivered through our partnership with Vetster. Our deep experience with the vet community is a significant competitive advantage. As we discussed in our last earnings call, we currently have one of the largest direct-to-consumer vet networks in the online retail space with over 70,000 veterinarians that we&#8217;ve worked with over the Company&#8217;s history.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Currently, our online vet portal has 17,000 active veterinarians and vet clinics. As I&#8217;ve said in earlier earnings calls, this is a core capability and a unique asset because it enabled us to expand our fulfilment capability as we scale our business. Our intent is to drive incremental revenue through a powerful platform offered to our vet partners in the near future. Unlike other online players, we don&#8217;t view vets as competitors for revenue, we view vets as partners in jointly providing a greater array of pet health services to pet parents. To that end, we will continue working together holistically to improve vet&#8217;s ability to care for pets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Because of our industry leading service relationships with vets, our prescription medication authorization rates are the highest they&#8217;ve ever been, which speaks volumes to the level of veterinary cooperation we receive on a daily basis. Ultimately, we believe if we help vets, the profits for both the vet and for PetMeds will follow. Our pet pharmaceutical category expertise is something that I view as a towering spring. Many retailers can sell dog food, but few can provide medication and sound advice at scale. As I&#8217;ve said before, being a differentiated pet medication provider allows PetMeds to excel in our health and wellness offerings and continue to be viewed as pet health experts, especially as the market continues to become even more competitive.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">PetMeds currently enjoys a close and strategic bond with our many supply partners and those relationships have developed over time to become even more strategic. We have direct relationships with all of our major suppliers, and we work together closely to effectively market their products to our customer base. Our customer service and overall customer centricity ethos permeates our culture and its demonstrated throughout our team. We provided 100% satisfaction guarantee to our customers, and we go the extra mile for our customers with truly empathetic and expert service. We don&#8217;t just have a transactional interaction with our customers, we have built trusting genuine relationships. Our customers view PetMeds as a trusted pet health expert, and we take that responsibility seriously.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I recently had the pleasure of listening to a phone interaction from loyal customer; here is what they had to say, &#8220;I just want to complement the two people that I spoke with. I called from the parking lot of the emergency clinic, which is open night and weekends. I told PetMeds about my situation. The representative that I talked to named Cindy bent over backwards to get this prescription to me the next day before the hospital even opened Monday morning. And then I called later that day to make sure that I could get the medication. I spoke to Gus, and I explained the situation and how I had to have this medication.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 3 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">And he said, I&#8217;m going to make sure that it&#8217;s in the mail for you. They were both absolutely wonderful. I can&#8217;t thank you guys enough. They were just fantastic and so sympathetic, and they understood how I was feeling. It&#8217;s kind of a cultural rehab. You&#8217;re not selling at PetMeds. This is not like buying food or music. These are our pets, and when they are sick, they are in real need. This is important.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cindy and Gus are perfect examples of our employees&#8217; dedication to our customers and their pet&#8217;s well-being, and I&#8217;m delighted to share this story and recognize them for their exemplary customer service.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">PetMeds has historically been a somewhat low growth yet high dividend-based company. We are intent, however, upon becoming a higher growth company and believe we are in a great position to do that. PetMeds is profitable with a pristine balance sheet. We do not have any debt, we have approximately $111 million in cash and cash equivalents as of March 31, 2022, and we are cash flow positive. PetMeds is moving much of our business from a transactional direct-to-consumer model to a subscription business. Subscription businesses are clearly compelling business models due to their predictable and stable recurring cash flows. As I mentioned at the beginning of the call, we ended the month of March with approximately 37% of our customers enrolled in ordering via our AutoShip &amp; Save subscription program, and we anticipate that this number will continue to rise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We continue to have a large base of returning customers, which is an indication of the quality of service and the value that we deliver. We are fortunate to have a large base of over 2 million pet parents that have purchased from us over the last two years. We have over 26 years of experience as a pure-play pet pharmacy, fully licensed in 50 states, delivering outstanding service and value. This domain experience is what I would call the more complicated part of the pet ecosystem, which make our progression in the other segments much easier. Our customers just love our brand and service. Our NPS score is over 80, which puts us in the upper quartile, along with some of the most beloved brands in the world.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Now I&#8217;d like to have Bruce review our financials for the quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thanks, Matt.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the review of our financial results, we will compare our fourth fiscal quarter, which ended on March 31, 2022, to last year&#8217;s quarter that ended on March 31, 2021. I would also like to highlight that we introduced new non-GAAP financial metrics last quarter, adjusted EBITDA and adjusted EBITDA per share. We decided to include these new metrics because they are key measures used by management and by our Board to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. Adjusted EBITDA and adjusted EBITDA per share provide a more accurate picture of our underlying profitability and also highlight the more recent increases in non-cash stock-based compensation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Throughout our most recent fiscal year, we faced a unique situation comparing two totally different environments between 2020 pandemic and 2021, mostly post pandemic. As we move forward into our first full fiscal year, the year ending March 31, 2023, with our new marketing partnerships, agencies and processes, and with many of our highlighted initiatives firmly in place, we expect to be much more efficient with our variable marketing spend with improved results. For the current year, fourth quarter sales were $66.0 million compared to sales of $71.7 million for the same period the prior year, a decrease of 7.9%. While we were disappointed with the overall sales results for the quarter compared to the prior year, we were encouraged by the sales trends we saw in January and February, which were only down in the low single digits. However, as Matt mentioned earlier, as a result of colder weather in the spring, we saw a delay in the flea/tick and heartworm season, resulting in a decrease in demand for flea/tick and heartworm control products in the month of March. In contrast, in the prior year, season started in early March.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A positive trend to highlight for the quarter was the continued growth of our AutoShip &amp; Save subscription program. Approximately 37% of our revenue in the month of March was generated from our AutoShip &amp; Save subscription program, with some of our more popular brands exceeding 41%, reflecting the alignment of our discount promotional offers, which required enrolment in the AutoShip program. Growing our subscription revenue is one of our main priorities in fiscal 2023 and we expect to see stronger reorder sales as our AutoShip revenue continues to grow.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the quarter, we saw decreases in both new orders and reorder sales. New order sales are obviously one area that needs improvement and we&#8217;re actively deploying new thinking and initiatives around re-energizing new customer growth.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 4 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">New order sales decreased by 35% to $4.9 million for the quarter compared to $7.4 million for the same quarter the prior year. We acquired approximately 53,000 new customers in our fourth fiscal quarter ended March 31, 2022, compared to 88,000 for the same period the prior year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Reorder sales decreased by 4.8% to $61.1 million for the quarter ended March 31, 2022, compared to reorder sales of $64.2 million for the same quarter the prior year. For the full year, reorder sales decreased by 8.2% to $250.4 million compared to $272.6 million for the prior year. With the increasing AutoShip subscription adoption rate, we will see more opportunities to continue to build our relationship with our loyal customer base. We will also work to continue to improve our reorder sales by marketing to our loyal customer base with increased product offerings and services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the fourth fiscal quarter, our gross profit as a percentage of sales was 29.4% compared to 28.6% for the same period a year ago. This percentage increase was due to some of our major manufacturers shifting their funding from cooperative marketing rebates to discounting product costs and also the funding of discount promotions related to AutoShip. There may be an opportunity to improve gross margins in fiscal 2023 if the shift to prescription medications continues and we can grow future sales without the reliance of price promotions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Net income was $6.1 million or $0.30 diluted per share, for the fourth quarter of fiscal 2022 compared to $6.8 million, or $0.34 diluted earnings per share, for the same quarter last year, reflecting a decrease to net income of 11%. Net income during the quarter was also aided by two tax benefits: a $196,000 state tax rebate related to 2020 and $131,000 state rate reduction in 2021, which was recognized in the March quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Adjusted EBITDA for the March quarter was $9.5 million, or $0.47 on a diluted basis, compared to $10.4 million, or $0.52 on a diluted basis, for the same quarter last year, reflecting a decrease to adjusted EBITDA of 8.4%. Adjusted EBITDA and adjusted EBITDA per share add back certain non-cash expenditures including stock compensation, interest income and expense, income taxes, depreciation and amortization. Again, adjusted EBITDA and adjusted EBITDA per share are non-GAAP key measures used by management and our Board to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. We will continue to disclose this financial measure in our future filings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As Matt mentioned earlier in the earnings call, adjusted EBITDA for the March quarter exceeded our expectations by being down only 8.4% for the fourth quarter ended March 31, 2022, compared to being down 31% in the third quarter ended December 31, 2021. Over the past six months, we have seen double-digit percentage increases in general and administrative expenses year-over-year due to the intentional and strategic incremental investments in both headcount and infrastructure. We will continue making purposeful investments in the business to fuel and support future growth. We also expect to see a continued investment in capital expenditures to the tune of approximately $5 million in fiscal 2023, of which $4.2 million is incremental to the business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We had $111 million in cash and cash equivalents and $32.5 million in inventory with no debt as of March 31, 2022. The Company continues to be committed to returning capital to our stockholders. As such, the Board of Directors declared a quarterly dividend of $0.30 per share on the Company&#8217;s common stock that will be payable on May 27, 2022, to shareholders of record at the close of business on May 20, 2022. Please note that the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company&#8217;s financial performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Now I&#8217;d like to hand the presentation back over to Matt.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thanks, Bruce.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We embarked on a new journey eight months ago when I joined the Company. In evaluating and planning for our future, we want to first to re-examine how we saw ourselves as a culture and company and then we dealt into redefining our Company&#8217;s core purpose. We looked at where we excel today in the market and how we consistently solve our customers&#8217; pain points and we use that as the starting place for our re-envisioning process. Through that work, we identified a clear market need to have a brand company focused on being THE trusted pet health expert. In many ways, we have served this function for our customers for over 26 years. If you think about it, selling prescription medication represents perhaps the most difficult corner of the pet ecosystem. It involves both collaboration with, and authorization from veterinarians - combined with dispensing controlled substances and complying with regulatory requirements, etc. In short, it&#8217;s hard.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 5 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">When you contact us either online or over the phone, we&#8217;re paying extra attention to your pets&#8217; specific health needs with important in customer-specific details, like monitoring for drug interaction and ensuring the accuracy of your pet prescription. We now have the capability to extend those demonstrated competencies much further. To that end, I am pleased to unveil our new vision and mission. Our vision, every pet deserves to live a long happy healthy life. Our mission, PetMeds aims to be the most trusted pet health expert by providing incredible care and services that are affordable to the broadest group of pet parents. In order to realize this vision, we need to execute on our mission through the strategy I would like to share with you next.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Next slide please. We are now ready to talk about our long-term strategy to some degree of specifics. We have been hinting at a larger strategy since I started at the business just eight months ago. PetMeds is moving from being just a leading pet medication retailer to a market leader in expert pet health care. We have already been given permission by our customers over the last 26 years to be our pet parents&#8217; trusted partner in caring for their pet. Pet parents are giving PetMeds permission to do more, and they want more. We have taken important steps towards executing on our long-term strategy, starting with the announcement that we made recently in the telemedicine space. The strategic pillars that we will be executing on are nutrition, medications, wellness and care with data both driving and being at the heart of our services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our recent announcement with Vetster is the first building block of our care offer. For instance, AutoShip is a fantastic program that allows pet parents to improve their pet&#8217;s care through cost savings, convenience and, most importantly, health compliance for their pet. But we think we can do more. In the future, we will be adding more capability and utility to this AutoShip service. Being the trusted pet health expert also means that we are not the same thing to all people. Like I said before, anyone can sell dog food, but that is a far different proposition than being the trusted health expert and consistently solving our customers&#8217; individual and unique pet health and wellness needs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On to the next slide so we can cover this recent partnership and announcement. We are really excited about telemedicine. We just announced a strategic new investment and partnership this quarter, including an exciting set of innovations that we think truly revolutionizes pet care. We announced a partnership with an early-stage venture capital-based company called Vetster. Vetster is a leading start-up in the pet space providing incredible services for both pets and vets. The company has led by a phenomenal team of seasoned and successful entrepreneurs. We are excited to offer what we think is the most advanced telemedicine platform on the planet. With this partnership, PetMeds leaps ahead of the other pet retailers and intermediaries and most importantly supports vets and pets like never before.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Now I&#8217;d like to provide an overview of the deal and deal structure. I have been intimating since I started at the Company that we are big believers in telemedicine. This deal is one of the many steps that PetMeds will be taking to cement our place as the go-to-expert pet health brand. PetMeds continues to have a strong balance sheet and we have indicated that we intend to put some of our $100 million-plus capital to work. This deal is evidence of that strategy, to not only make smart deals but to show management&#8217;s willingness quickly to turn PetMeds into a growth company. Here is an overview of our deal with Vetster. PetMeds is the exclusive pet medication provider to Vetster, and Vetster is the exclusive telemedicine provider to PetMeds, a $5 million investment and a minority stake at Vetster as part of the Series B round of funding, ability to grow PetMeds ownership share in the form of performance-based warrants, based on specific performance objectives, mutually exclusive long-term agreement to work together to build new distribution channels and never before seen customers experiences.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The technology and e-commerce integration provides a powerful combination that has never been introduced in the pet category. We see a panoply of upside in opportunities, including first mainstream launch - we believe we are the first company to introduce pet telemedicine into the mainstream connecting over two million pet parent customers with over 70,000 veterinarians in the PetMeds network. Close the loop - direct connect access to a telemedicine experience that closes the loop between the pet parent and a vet so that the prescription medication can be prescribed directly to a pet parent in many cases without the need of an in-office visit. New revenue streams - this partnership creates new revenue streams within PetMeds and the potential for new revenue streams from traffic driven from Vetster&#8217;s platform. Go-to-market acceleration - unique investment and partnership terms allow Pets to accelerate our go-to market on our new strategy. For example, PetMeds will leverage the Vetster platform to provide virtual vet clinic services embedded with our pet medication and retail platform directly into their platform. Climbing up the sales funnel - we believe that offering telehealth will enable us to acquire new customers and to create more incentives for PetMeds subscribers. PetMeds customers will be able to get instant care. Whether that is text or live video chat with your vet or any vet provider through an exclusive vet marketplace accessed on your smartphone or desktop 24/7. Veterinary alliance - we think that this partnership is a huge win for vets, too. We believe this partnership will allow us to provide attractive capabilities and additional revenue streams to our core vet network and beyond. Oh, and we also plan to dream up a bunch of new innovations that we&#8217;re not ready to talk about yet.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 6 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The deal in the short term should do the following for the PetMeds&#8217; business. Attracting new customers - adding more utility to our AutoShip capability will help us attract new customers through adding new and exclusive telemedicine and pet parent medical functionality. This will greatly differentiate us in the marketplace and allow us to not focus solely on pricing and discounts. Driving more subscribers - adding more utility, like I mentioned above, will also enable us to increase the acceleration of converting our existing customers to our subscription offering. Today, that number of 37%, and we would like to see that number exceed 50% in the full year 2023. Driving more prescription business - today, the process of getting pet authorization required our well-honed pharmacy to obtain an authorization from the pet parents veterinarian. While authorizations are high, we still lose some prescriptions due to the need to physically see a vet. With this technology, customers will be able to connect to their established vet for a virtual visit and subsequently have their prescriptions authorized. Additional revenue streams - we will be connecting pet parents to vets and we will be able to participate on a revenue share basis for each paid virtual vet appointment, both on the PetMed&#8217;s platform. In addition, PetMeds will participate in incremental Rx and OTC revenues that are booked through the Vetster platform. We have long thought that there was more we could do to support vets. PetMeds plus Vetster enables vet and vet clinics to have the flexibility to work whenever and wherever they want. Quality pet health care will literally now be at the fingertips of PetMeds pet parents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I have talked about how our network of over 70,000 vets is a strategic asset. We hope to turn that asset into a partnership that helps the vet community by allowing more productivity, flexibility and more revenue for our vet partners. We&#8217;ve been very intentional about continuing to build our vet relationships. We believe that this is a real game changer for vets, pets and pet parents. Our combined goals to make quality pet health care more accessible, affordable and available to pet parents and pets everywhere. We believe pet telemedicine will be as big a trend as it is in human health care, and we are excited about the possibilities that this partnership will unlock for all of our shared stakeholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We see a great future in adding more health and wellness services to our business and especially growing our e-commerce subscription base well beyond our current levels. We have a lot left to do, and growing our new customers is certainly a huge focus for the Company. I hope this level of detail and transparency demonstrates our confidence in the future of the business, while also providing some insight into the associated investment costs and activities, as they are reflected in our operating results.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This ends our prepared remarks. Operator, we are now ready to take questions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thank you. The first question is from the line of Erin Wright with Morgan Stanley. Please proceed with your question.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Erin Wright</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Great. Thanks for taking my questions here.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">What are you seeing, quarter to date, in terms of demand trends in the progression of the flea and tick season that you said it was off to a somewhat slower start here, but should we anticipate a meaningful bolus here associated with parasiticides in the current quarter? How do you anticipate that playing out from what you&#8217;re seeing? Thanks.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Bruce, do you want to take that, and I can follow?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sure. Erin, how are you doing? As we mentioned during the quarter, we started out very strong. Obviously, once we hit March, we definitely saw a drop in demand unlike what we saw on the previous March 2021. We&#8217;ve also have gotten similar information for manufacturers of this slow flea and tick season. So that&#8217;s something that I think all of us have had seen. In the past, we&#8217;ve gone through delays in the season. Our season coming early in the year. I would say that, traditionally, it&#8217;s a six-month period. In the past, it has extended. We&#8217;ll just have to see how it plays out in the current quarter and&#8212;but yes, we definitely saw that in March and we&#8217;ll see how it shakes out for the June quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 7 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes, the only thing I&#8217;ll add is&#8230;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Erin Wright</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Okay.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The only thing I&#8217;d add to that, Bruce, to what Bruce said is we do have a concentration of flea and tick and heartworm. And so, we are feeling quite confident that clients we&#8217;re starting to even out in January and February and so unfortunately you can&#8217;t control the weather. I mean, we do have category concentration of those areas. So we&#8217;re confident that we have a very long loyal returning base. So when the earth heats up, we anticipate that reorders will kind of get back to where we expected them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Erin Wright</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Okay, and then two quick follow-ups here. Given some of the initiatives around advertising and the spend for the quarter, how should we be thinking about advertising spend in Fiscal 2023? I mean, should we anticipate a step-up from here as a percentage of sales in the coming quarters? I guess help us frame that in terms of how you&#8217;re thinking about advertising spend. And then in terms of the telemedicine partnership, can you describe a little bit more on the financial contributions for you and will this be material for you, near term? Thanks.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes, I&#8217;ll take the last question first, and then throw it over to Bruce. I think on the telemedicine piece, it is a pretty exciting opportunity since we are in the prescription space as a core offering to consumers. Obviously, we want to be in front of that trend of having consumers literally at their fingertips, have the ability to connect to a vet either on their desktop or on their mobile device and have prescriptions delivered to their to their doors. We aren&#8217;t really guiding to ho big this opportunity is, it&#8217;s really, really new. The VCPR realizations which connect the consumer with a vet are relatively new as well. We see the regulations loosening over time. And that we see more demand for consumers. So we&#8217;re not really guiding per se and we love to excite from the upside as this partnership develops. Partnerships are very hard to forecast, as you know, but we&#8217;re very excited about it, and we think this is the best team in the pet telemedicine space in Vetster. This is a seasoned team that we&#8217;ve started to get to know very well. They come highly recommended from the travel space, and they know marketplace is extremely well and that had multiple successes of building out marketplaces. So we&#8217;re highly confident that this is the right team and product and business model for us to put our bet around and to start growing demand around.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On the &#8212; the other comment. Bruce, do you want to take that? And I&#8217;ll follow.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sure. As far as advertising, so for the quarter, advertising was down about $800,000 or about 20% from where we were last year. And I would say that we were somewhat on target to spend somewhat similar to where we spent in the previous year. Obviously, the slow start to season, we pared back our spend due to that, and we expect to spend probably similar to what you saw last year, but we expect to be more, much more, efficient with our spend and these areas that we can lean in that are producing a much better return obviously we&#8217;ll take advantage of that when we see it.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes, the only thing I&#8217;d add to that too. It&#8217;s exactly right, is we want to make sure we were spending money when there is demand because consumers we&#8217;re pairing back flea and tick and heartworm. We decided not to accelerate that. The other thing that we decided to do is introduce this LTV to CAC number in the 2.5x that you saw. That could &#8212; that could change over time, as we start to in front invest. We want to be very smart about how we scale or demand, 2.5 may be on the high end. It could be lower than that and just depends on the types of consumers that we&#8217;re finding and where we think where there&#8217;s a spot to invest. So that gives you some direction of where we&#8217;re going, but it should be higher than you&#8217;ve seen in the past, but we&#8217;re going to be very performance oriented around that the 2.5x that is a pretty efficient LTV to CAC. I think that might move around a little bit.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 8 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Erin Wright</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Okay, great. Thank you so much.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The next question comes from the line of Corey Grady with Jefferies. Please proceed with your question.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corey Grady</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Hi, thanks for taking my questions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I wanted to follow-up on the new marketing strategies and partnership and maybe can you spend a little more time talking about areas where you&#8217;re seeing signs of validation in terms of return in areas where you are continuing to test?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Hi, thanks for the question, and I&#8217;ll jump in on this one.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes. Again, I want to remind you and I think you know that we after our discussions that much of what we&#8217;ve done to date has been really building kind of a basis, a platform for growth. As you can recall last quarter, we had some inefficiencies, we implemented new marketing operations technology, new marketing partners. And we&#8217;ve been really testing a lot. We&#8217;ve been testing new customer segments that are going to be younger, more digital native, and I think the headline is we&#8217;re seeing a lot of interest pet health expert strategy standing for something that&#8217;s more positioned around your pet health versus kind of a broader play with everything store for a pet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Really, consumers are responding to that. So we&#8217;re going to adjust our positioning in our creative around that game, and we&#8217;re starting to see some early positive signals around that. And as that starts to scale, I think our media mix will scale. I think with the way we spend our dollars will definitely scale and will scale profitably. I would like to point out there is a 1,000 out of the 3,000 Russell 3,000 companies that are not profitable. We tend to grow profitably and find that new customers, and like I said on the earnings call, really, customers understand that PetMeds stands for pet health care, and I think that&#8217;s really exciting proposition for customers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corey Grady</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Got it. That&#8217;s helpful. And then I was wondering for my second question if you could quantify the sales impact from that whether the flea and tick season. And then how did results for the quarter in terms of sales composition reorder versus new order, how does that compare to your expectations coming into the quarter?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I&#8217;ll start, and then, Bruce, do you want to finish?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes. As we said on the earnings call, January and February were trending, actually, to where we wanted to. We started to see the evening out of those comps. It was a really important metric for us and I think we&#8217;ve been really transparent about net new customer growth has been an issue for the Company for a while, something that we&#8217;re going to continue to work on and we&#8217;re actually pretty optimistic that that will improve. And unfortunately, March was just colder than anticipated. So we were anticipating returning customers to be more flat year-over-year than what you saw.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Bruce, do you want to add any other color to that?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 9 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Bruce Rosenbloom</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I would say that I think, obviously, the surprise in March. I mean, we look at the two Marchs, the season was really strong last year. So our reorder numbers were much higher. I would just say that you&#8217;re comparing two totally different Marchs between early on-time season versus a delayed season. And so, you have those two dichotomies there. But again, I think reorders we&#8217;re probably out of the two. The reorders were probably more affected from the delay in season than when what we would expect to going into March quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corey Grady</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Got it. Thank you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The next question comes from the line of David Maley with 1102 Partners. Please proceed with your question.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>David Maley</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Hi, Bruce. Hi, Matt.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">You mentioned that the Vetster deal is the first of many transactions, should we expect transactions of similar size, or is it likely that there might be something that&#8217;s much bigger down the road? And I guess if so, would that be the deal that would lead you to eventually pare the dividend?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thanks. To answer your question, I think there&#8217;s two parts to that obviously. I&#8217;ll take the first part, and then I&#8217;ll take the second part.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The capital allocation side is we have a lot of cash, and the cash hasn&#8217;t really been put to use, and so as we fill out those puzzle pieces that I mentioned on the call around care, around wellness, diet, medication, we think we&#8217;re pretty good at medication and there&#8217;s other areas where really need to fill in. And what&#8217;s driving that is really our customers really want to have more products. They want more basket from us. They want more services that are aligned around pet health, and that&#8217;s driving really some of our thoughts around how to accelerate, whether it&#8217;s an investment, M&amp;A, or an investment partnership that you saw in Vetsters. So we&#8217;re going to continue to look at those types of opportunities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Things that we discussed in earnings calls like insurance certainly lead to more of a partnership type of profile. But certainly, we&#8217;re open to M&amp;A as well. As asset prices start to settle down, the economy starts to change, I think there could be some more buying opportunities there. But we&#8217;re open to filling in those puzzle pieces using cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On the dividend side, we have a commitment to the dividend. One of the things that we&#8217;re looking at as a management team that we discussed all the time as new customer growth starts to get figured out and we have better calculus around that, we understand the types of recurring customer acquisition. We can start driving. That&#8217;s probably the time that we start discussing how fast we want to grow the Company. But as you know, we&#8217;ve struggled with, new customer growth and so we&#8217;ve decided to support the dividend, and we&#8217;ve also decided to also not grow the Company unprofitably. We are not deciding to take this business down to a profitable&#8212;an unprofitable business, which a lot of e-commerce companies have decided to do. And I should think that could be a problem as you start entering into some of these more difficult periods that we&#8217;re starting to see now. In short, we&#8217;re going to support the dividend. We&#8217;re certainly having conversations with the Board all the time, but we&#8217;re actually excited about growing through investments through partnerships and M&amp;A and we generate a lot of cash. So there is an opportunity for us to do both.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The good news about the pet health space is there&#8217;s a lot of companies, there&#8217;s a $100 billion space, and there&#8217;s a lot of companies that want to work with us. Like I said on the call, there&#8217;s not many pet prescription companies, and a lot of folks want to work with us, and it gives us an opportunity to generate terms like you saw in the Vetster deal that are probably a little bit more unusual than you&#8217;ve seen somewhere else, with the performance warrants. So that&#8217;s a long-winded answer to look when we decided that we can really ramp new customer growth, we&#8217;ll certainly discuss at the Board. Until then, there&#8217;s a lot of opportunity for us to find inorganic or semi-organic growth through partnerships. I hope that answers your question. If not, I can keep going.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 10 of 11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>David Maley</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Yes, no, that&#8217;s good, that&#8217;s good color. Really appreciate it. Thank you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Great question. Thank you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There are no further questions at this time. I will now turn the presentation back to the host.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Matt Hulett</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thank you, Operator.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As you just heard, the future of PetMeds is much broader than just the prescription e-commerce company. We are building our strategy out and working hard to transform into a broader e-commerce and subscription brand that reflects and leverages our status as the trusted pet health experts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I will continue to detail our progress and look forward to providing you with updates in the not-too-distant future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As always, thank you to all of our employees, customers, partners, suppliers and investors for your continued confidence and support.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thank you for listening in.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Operator, this ends the conference call.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Operator</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">That does conclude today's conference. We thank you for your participation and ask that you please disconnect your line.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="Exhibit 99.1 Page " data-suffix=" of 11" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exhibit 99.1 Page 11 of 11</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pets-20220509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/12/2022 11:57:08 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:pets="http://www.pets.com/20220509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pets.com/20220509">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20220509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20220509_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20220509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.pets.com/20220509/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="pets_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pets-20220509_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/12/2022 11:57:08 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.pets.com/20220509/role/statement-document-and-entity-information" xlink:href="pets-20220509.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.pets.com/20220509/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pets-20220509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/12/2022 11:57:08 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pets-20220509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/12/2022 11:57:08 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.pets.com/20220509/role/statement-document-and-entity-information" xlink:href="pets-20220509.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.pets.com/20220509/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140324655465112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">PetMed Express, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">May  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-28827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">65-0680967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">420 South Congress Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Delray Beach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">33445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">526-4444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PETS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001040130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>pets20220511_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pets-20220509.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001040130</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">PetMed Express, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">000-28827</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">65-0680967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">420 South Congress Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Delray Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">33445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">526-4444</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20228K">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">PETS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M\I*G"Z[K2' 1W_<OZ&! KQ"@00DT. MHSC9D$L&ZBJ4(=^5U&@^7[/<N_/[
MO^YC?-<EW_59?.,HVA73_H04M?]5UBXD+MFE/IG!SA1#(LA5(39^YS+G"&[@
M5T;J?PSXSGDI9-]<K>M]%->[YXF&.KGE+(PQP".G#SX&6-;'5*MW(</:D#:(
MHL415"X?T(^Q396Q+"%_B>QDU39(=CK=;@^#J[:' +?U8B''\,YS&@47Z/4#
M#*3:!P+<R)]4"#&9QDIB'M(@TJ/]BR[\8435GA#@3OY="VNYA,"D:2[W!F)J
MJ7"A)4L,6H?57A#@=CU3B0B%%7)%GB&_M6!)+0^NTLA3&7^ F_94\XL0PL.A
MP(HWF3F7$=?DZW)Y8OUPO4:R:@<(<+_^']G$F!S(&@%QV4; :@L(<,.>"PN[
MI5J2@/ZR^)7,>)A#OFUKF7 EEY^PL\VL"M_:)&.:O+,DY^3G2]\/2 :S-3'3
M&#6M-@**&_=<L\AEWVR;+E1M[C4(3!_F,XRD<GR*F_,A8/!&&L9,KOC)]]H&
MH9?Q['[\#6,Z>I\_S^D?4JY7+DR_@42Q):<9D[5KVZ#8E&^T,GJ*^_08JB J
M*N$Q8:M:%%R@$:6R>HJ[]"%,=T"CP?0G4)(;\H77!PC7@M?&P._Z0<>O0_..
M/A[=A_@S<^MB2,*7H.9?7H%QZ]VW[>["JJSXGEPH"U^GQ6G,&3B&:P#/ETK9
MPX7[1"U_81C]!U!+ P04    " "]4:Q4GZ ;\+$"  #B#   #0   'AL+W-T
M>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/Z
MZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N
M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2
MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(
M&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=
MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-
M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]
MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU
MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>
MDO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A
M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[
M7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..V
MBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/
M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>
MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%'
M, ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "]4:Q4EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +U1K%0Z
MJJ+G0 $  #P"   /    >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@2<M6
M6&D&8]U'86QE'7UW8J41M:U@J^W67S\E(:RPESW).HG3W7EQHK@OB?;JR[N0
M"MTPM_,L2U4#WJ0K:B'(I*;H#4L;=UEJ(QB;&@#V+IOF^2SS!H.^6XQ<ZYA=
M-L10,5(0L .V"*?T.^]:=<2$)3KD[T+W;P=:>0SH\0RVT+E6J:'3"T4\4V#C
M-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[
M](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :
M;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#
MV#<YD 27Y*IU5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @
MO5&L5"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ O5&L5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "]4:Q4I0B1
M^N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "]4:Q4F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +U1K%3LQ%TS000  &T0
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "]4:Q4GZ ;\+$"  #B#   #0              @ &%#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +U1K%27BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pets20220511_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pets.com/20220509/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="pets20220511_8k.htm">pets20220511_8k.htm</File>
    <File>ex_374831.htm</File>
    <File>pets-20220509.xsd</File>
    <File>pets-20220509_def.xml</File>
    <File>pets-20220509_lab.xml</File>
    <File>pets-20220509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pets20220511_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "pets-20220509_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pets20220511_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pets-20220509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pets-20220509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pets-20220509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pets",
   "nsuri": "http://www.pets.com/20220509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pets20220511_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.pets.com/20220509/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pets20220511_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pets.com/20220509/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001437749-22-012031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-012031-xbrl.zip
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MQZ?O;O]&+]8I3M_\Z?RS[Q^_^/;Q%\7C__[^V>/GSV?%D^\>G7_Z[ORSO_M
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MLK)RK$0LRAQ67;N15[6T$MH?99!0["^22"T8-QC*:WE)(ZII7OL.8]+;)4[
MP5#CHO?CO(>1(?/5>9T7/]@:B\:1H:\J^2)N?#OVG%FQ$O4C2ABS:45VPQ;
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M9@?HXZSXNNPZQI<]ZY@\"::J98JWHFT8,Y")AVN98KT\Q8/RC1X2C:Q:EA6
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MD2SZ<G&=.51B'?QR)/>?]!*_F";9\K8663<T7N!525BV@WU2&%POM7-M#>U
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M^Q=,X%MZ6EZ=$3V'E,YJBC:C2)U4<[RKO LH%N!+Y]N/(@Y)LO]2.UR@Y6K
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M29L,^^/3\;[Z4/^M*^_\#U!+ P04    " "]4:Q42:#*2OT%  "L/   %0
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ME2@JJCI%H-Q#J&R.-1@&D)"(<$(GG\0<A)$PT9!@#JJ)P7XBVPR\***UI%,
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M,#(R,#4P.5]L86(N>&UL4$L! A0#%     @ O5&L5(:H@0UW!   YBT  !4
M             ( !A%@  '!E=',M,C R,C U,#E?<')E+GAM;%!+ 0(4 Q0
M   ( +U1K%2[0\C2YP\  $II   3              "  2Y=  !P971S,C R
B,C U,3%?.&LN:'1M4$L%!@     &  8 A $  $9M      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
